Inclusion Criteria shared:
- Histologically proved seminoma after orchiectomy
- Primary testicular or retroperitoneal
- Normal alpha-fetoprotein before and after orchiectomy
- No prior treatment with radiotherapy or chemotherapy
- Age >= 18 years
- ECOG 0 to 2
- PNN >= 1500, platelets >= 100 000, bilirubin <= the upper limit nromale
- ASAT (SGOT) and ALAT (SGPT) <= 1,5 x the upper limit nromale
- Serum creatinine <140 µmol / L (or clearance> 60 mL / min)
- Information and signed informed consent before inclusion in the study
- Patient affiliated to a social security
Specific inclusion criteria for cohort 1:
Specific inclusion criteria for cohort 2:
- grade IIB (retroperitoneal adenopathy diameter between 2 cm and 5 cm, regardless of the LDH)
- grade IIC (retroperitoneal adenopathy diameter higher than 5 cm, regardless of the LDH)
- grade III of good prognosis (supradiaphragmatic reach with ganglionic metastasis and LDH < 2 times normal limit and/or supradiaphragmatic reach with pulmonary metastasis and LDH < 2 times normal limit) either at initial diagnosis or relapse of a grade I seminoma)
- PET-TDM positive (pathological fixation on metastatic lesions)
Exclusion Criteria shared:
- Patient infected by HIV, Hepatitis B or C
- History, within 5 years, of cancer other than seminoma, except for treated skin cancer (Basal Cell) .
- visceral metastasis
- cerebral metastasis
- Any physical or mental condition incompatible with the treatment (to the investigator discretion)
- Uncontrolled or severe cardiovascular pathology
- Uncontrolled or severe hepatic pathology
- Persons deprived of liberty or under guardianship
- Unable to undergo medical monitoring due to geographical, social or psychological reasons